Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MB | P02144 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1570132 | 0.86 | LMNA (0.52) | LMNASMN1; SMN2HSD17B10HTTL3MBTL1 | |
| SCHEMBL25360083 | 0.78 | LMNA (0.45) | LMNASMN1; SMN2HSD17B10HTTL3MBTL1 | |
| SCHEMBL10882572 | 0.78 | LMNA (0.61) | LMNASMN1; SMN2HSD17B10HTTL3MBTL1 | |
| SCHEMBL25522846 | 0.77 | LMNA (0.58) | LMNASMN1; SMN2HSD17B10HTTL3MBTL1 | |
| SCHEMBL18109247 | 0.77 | MEN1 (0.44) | LMNASMN1; SMN2HSD17B10HTTL3MBTL1 | |
| SCHEMBL1570394 | 0.73 | LMNA (0.40) | LMNASMN1; SMN2HSD17B10HTTL3MBTL1 | |
| SCHEMBL2894937 | 0.73 | KIF11 (0.46) | LMNASMN1; SMN2L3MBTL1MAPTCYP1A2 | |
| SCHEMBL4628395 | 0.73 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2HSD17B10HTTL3MBTL1 | |
| SCHEMBL1569968 | 0.72 | ALDH1A1 (0.41) | LMNASMN1; SMN2HSD17B10HTTL3MBTL1 | |
| SCHEMBL16050414 | 0.72 | NAPRT (0.53) | SMN1; SMN2HSD17B10HTTL3MBTL1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102123991-A | 2-arylaminoquinazolines for the treatment of proliferative diseases | NOVARTIS AG | 2011-07-13 | — | — | CN | disclosed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| CN-101652352-A | Quinazolines for PDK1 inhibition | NOVARTIS VACCINES & DIAGNOSTIC | 2010-02-17 | — | — | CN | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | LMNA 2948/4885SMN1; SMN2 3375/4885HSD17B10 1460/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | LMNA 2647/4885SMN1; SMN2 2726/4885HSD17B10 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.